LIR Life Sciences Corp.
SKNY
CNSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 12.20K | 7.30K | 7.30K | 7.30K | -- |
| Gross Profit | -12.20K | -7.30K | -7.30K | -7.30K | -- |
| SG&A Expenses | 2.46M | 1.77M | 470.90K | 361.20K | 300.60K |
| Depreciation & Amortization | 3.70K | 2.80K | 1.80K | 800.00 | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.52M | 1.79M | 480.00K | 369.30K | 300.60K |
| Operating Income | -2.52M | -1.79M | -480.00K | -369.30K | -300.60K |
| Income Before Tax | -2.86M | -1.99M | -479.90K | -369.40K | -300.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.86 | -1.99 | -0.48 | -0.37 | -0.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.86M | -1.99M | -479.90K | -369.40K | -300.60K |
| EBIT | -2.52M | -1.79M | -480.00K | -369.30K | -300.60K |
| EBITDA | -2.51M | -1.63M | -241.50K | -101.10K | -- |
| EPS Basic | -0.11 | -0.08 | -0.05 | -0.65 | -1.31 |
| Normalized Basic EPS | -0.07 | -0.05 | -0.03 | -0.41 | -0.82 |
| EPS Diluted | -0.11 | -0.08 | -0.05 | -0.65 | -1.31 |
| Normalized Diluted EPS | -0.07 | -0.05 | -0.03 | -0.41 | -0.82 |
| Average Basic Shares Outstanding | 94.29M | 84.43M | 60.14M | 40.80M | 21.85M |
| Average Diluted Shares Outstanding | 94.29M | 84.43M | 60.14M | 40.80M | 21.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |